ACAleck Cervantes

Aleck Cervantes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Aleck Cervantes has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Interpretable Active Learning for Pedigree Data Deduplication in Cancer Genetics

    by Maria S. Rosito, Aleck E. Cervantes, Christine Hong, Joseph D. Bonner, Bita Nehoray, Alison Schwartz Levine, Danna Rosenberg, Isabel Anez-Bruzual, Giovanni Parmigiani, Christopher I. Amos, et al.

    PURPOSE: Studying rare genetic conditions often requires multicenter research to gather sufficient data. However, data from multiple institutions may include relatives from the same family enrolled at different sites, increasing the likelihood of duplicate records. This issue is compounded by the use of deidentified data, which limits the direct linkage through personal identifiers. These redundancies can bias family-based genetic studies underscoring the need for robust methods for pedigree deduplication. We propose an interpretable, active learning–based approach to efficiently identify duplicate records in genetic studies, with specific application to families with TP53 mutations in the Li-Fraumeni and TP53 : Understanding and Progress (LiFT UP) study. MATERIALS AND METHODS: Our approach combines heuristic labeling with graph-based features and a machine learning model to iteratively refine duplicate detection. We first generate a partially labeled data set leveraging mutation variant diversity and family characteristics. A random forest classifier is then trained to predict duplicate pairs, with active learning guiding iterative refinement. This method is applied to real-world pedigree data from the LiFT UP study to assess its effectiveness in a multicenter setting. RESULTS: Our method labeled pedigree pairs in data from the LiFT UP study with a high degree of automation, achieving 99.95% automated processing in the deduplication workflow. By prioritizing likely duplicates for human review, it minimized manual effort while aiming for high specificity. This automated approach avoids dependence on rule-based filters, such as identifier matching, which ultimately require manual confirmation, offering a more scalable solution for improving data quality in risk estimation. CONCLUSION: Interpretable active learning provides an effective solution for pedigree deduplication. Future work will explore refinements in identifying potential duplicates and evaluate its generalizability across other genetic data sets.

  • Open Access

    Data from Clonal Hematopoiesis and Mosaicism Revealed by a Multi-Tissue Analysis of Constitutional TP53 Status

    by Danielle Castillo, Tze-An Yuan, Bita Nehoray, Aleck Cervantes, Kevin K. Tsang, Kai Yang, Sharon R. Sand, Janet Mokhnatkin, Josef Herzog, Thomas P. Slavin, et al.

    Background:Though germline TP53 pathogenic/likely pathogenic variants (PV) are associated with Li–Fraumeni syndrome, many detected by multigene panels represent aberrant clonal expansion (ACE), most due to clonal hematopoiesis (CH). Discerning ACE/CH from germline variants and postzygotic mosaicism (PZM) is critically needed for risk assessment and management.Methods:Participants in the Li-Fraumeni & TP53 Understanding & Progress (LiFT UP) study with a TP53 PV were eligible. Demographics, personal/family cancer history, and clinical laboratory test reports were obtained. DNA from multiple tissues was analyzed using a custom QIAseq assay (ACE panel) that included TP53 and other CH-associated genes; the ACE panel and eyebrow follicles were assessed in a workflow to discern TP53 PV clinical categories.Results:Among 134 participants there was a significant difference for the age at diagnosis (P < 0.001), component cancers (P = 0.007), and clinical testing criteria (P < 0.001), comparing germline with PZM or ACE. ACE panel analysis of DNA from 55 sets of eyebrow follicles (mean 1.4 ug) and 36 formalin-fixed, paraffin imbedded tissues demonstrated low variance (SE, 3%; P = 0.993) for TP53 variant allele fraction, with no significant difference (P = 0.965) between tissue types, and detected CH gene PVs. Of 55 multi-tissue cases, germline status was confirmed for 20, PZM in seven, ACE for 25, and three were indeterminate. Additional CH variants were detected in six ACE and two germline cases.Conclusions:We demonstrated an effective approach and tools for discerning germline TP53 status.Impact:Discernment of PZM and TP53-driven CH increases diagnostic accuracy and enables risk-appropriate care.

  • Open Access

    Supplementary Figure from Clonal Hematopoiesis and Mosaicism Revealed by a Multi-Tissue Analysis of Constitutional TP53 Status

    by Danielle Castillo, Tze-An Yuan, Bita Nehoray, Aleck Cervantes, Kevin K. Tsang, Kai Yang, Sharon R. Sand, Janet Mokhnatkin, Josef Herzog, Thomas P. Slavin, et al.

    Supplementary Figure from Clonal Hematopoiesis and Mosaicism Revealed by a Multi-Tissue Analysis of Constitutional TP53 Status

  • Clonal Hematopoiesis and Mosaicism Revealed by a Multi-Tissue Analysis of Constitutional TP53 Status

    by Danielle Castillo, Tze-An Yuan, Bita Nehoray, Aleck Cervantes, Kevin K. Tsang, Kai Yang, Sharon R. Sand, Janet Mokhnatkin, Josef Herzog, Thomas P. Slavin, et al.

    Background: Though germline TP53 pathogenic/likely pathogenic variants (PV) are associated with Li–Fraumeni syndrome, many detected by multigene panels represent aberrant clonal expansion (ACE), most due to clonal hematopoiesis (CH). Discerning ACE/CH from germline variants and postzygotic mosaicism (PZM) is critically needed for risk assessment and management. Methods: Participants in the Li-Fraumeni & TP53 Understanding & Progress (LiFT UP) study with a TP53 PV were eligible. Demographics, personal/family cancer history, and clinical laboratory test reports were obtained. DNA from multiple tissues was analyzed using a custom QIAseq assay (ACE panel) that included TP53 and other CH-associated genes; the ACE panel and eyebrow follicles were assessed in a workflow to discern TP53 PV clinical categories. Results: Among 134 participants there was a significant difference for the age at diagnosis (P < 0.001), component cancers (P = 0.007), and clinical testing criteria (P < 0.001), comparing germline with PZM or ACE. ACE panel analysis of DNA from 55 sets of eyebrow follicles (mean 1.4 ug) and 36 formalin-fixed, paraffin imbedded tissues demonstrated low variance (SE, 3%; P = 0.993) for TP53 variant allele fraction, with no significant difference (P = 0.965) between tissue types, and detected CH gene PVs. Of 55 multi-tissue cases, germline status was confirmed for 20, PZM in seven, ACE for 25, and three were indeterminate. Additional CH variants were detected in six ACE and two germline cases. Conclusions: We demonstrated an effective approach and tools for discerning germline TP53 status. Impact: Discernment of PZM and TP53-driven CH increases diagnostic accuracy and enables risk-appropriate care.


  • Open Access

    Confirmation and refinement of the heterozygous deletion of the small leucine-rich proteoglycans associated with posterior amorphous corneal dystrophy

    by Aleck E. Cervantes, Katherine M. Gee, Martha F. Whiting, Ricardo F. Frausto, Anthony J. Aldave

    Purpose: To present the clinical and cytogenetic features of a previously unreported family with posterior amorphous corneal dystrophy (PACD) associated with a heterozygous deletion of the small leucine-rich proteoglycan (SRLP) genes on chromosome 12. Methods: Clinical characterization was performed using slit lamp biomicroscopic and optical coherence tomography (OCT) imaging. Genomic DNA was collected from affected and unaffected family members, and a cytogenomic array was used to identify copy number variations (CNV) present in the PACD locus. Results: Three members of a Guatemalan family presented with clinical characteristics consistent with PACD: bilateral posterior stromal lamellar opacification, decreased corneal curvature, and iridocorneal adhesions. OCT imaging demonstrated decreased corneal thickness and hyperreflectivity of the posterior third of the corneal stroma. CNV analysis confirmed the presumed clinical diagnosis of PACD by revealing a 0.304 Mb heterozygous deletion in the PACD locus on chromosome 12 that included the four SLRP genes (KERA, LUM, DCN, and EPYC) deleted in each of the PACD families in which CNV analysis has been reported. Conclusions: This is the first report of the OCT appearance of PACD and the second confirmation of a heterozygous deletion of chromosome 12q21.33 as the cause of PACD, highlighting the utility of array-based cytogenomics to confirm the suspected clinical diagnosis of PACD. As the smallest previously reported pathogenic deletion was 0.701 Mb, the 0.304-Mb deletion we report is the smallest identified to date and reduces the size of the PACD locus to 0.275 Mb.